Drug Profile
Rilzabrutinib - Principia Biopharma
Alternative Names: PRN 1008; SAR-444671Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Principia Biopharma
- Developer Principia Biopharma; Sanofi
- Class 2 ring heterocyclic compounds; Amines; Anti-inflammatories; Antianaemics; Antiasthmatics; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Idiopathic thrombocytopenic purpura
- Phase II Asthma; Atopic dermatitis; Autoimmune disorders; Autoimmune haemolytic anaemia; Chronic urticaria
- Discontinued Pemphigus; Pemphigus vulgaris
Most Recent Events
- 25 Mar 2024 Sanofi initiates a phase I bioavailability trial for Autoimmune disorders (in volunteers) in the US (NCT06342700)
- 25 Mar 2024 Sanofi plans a phase I bioavailability trial in Autoimmune disorder (In volunteers) in March 2024 (PO, Tablet) (NCT06342700)
- 15 Mar 2024 Discontinued - Phase-II for Pemphigus vulgaris in France, Israel, Croatia, Greece, Australia (PO), before March 2024 (Sanofi Pipeline, March 2024)